Squarepoint Ops LLC Raises Stock Position in Janux Therapeutics, Inc. $JANX

Squarepoint Ops LLC grew its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) by 230.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 189,569 shares of the company’s stock after acquiring an additional 132,121 shares during the period. Squarepoint Ops LLC owned about 0.32% of Janux Therapeutics worth $4,379,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its stake in Janux Therapeutics by 175.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after purchasing an additional 2,502 shares during the period. Lazard Asset Management LLC grew its holdings in Janux Therapeutics by 64.8% during the 2nd quarter. Lazard Asset Management LLC now owns 99,858 shares of the company’s stock valued at $2,306,000 after buying an additional 39,278 shares in the last quarter. Engineers Gate Manager LP raised its position in shares of Janux Therapeutics by 115.0% during the second quarter. Engineers Gate Manager LP now owns 39,749 shares of the company’s stock valued at $918,000 after buying an additional 21,258 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Janux Therapeutics by 185.1% in the second quarter. BNP Paribas Financial Markets now owns 7,673 shares of the company’s stock worth $177,000 after buying an additional 4,982 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Janux Therapeutics by 14.7% during the second quarter. Bank of America Corp DE now owns 859,423 shares of the company’s stock worth $19,853,000 after acquiring an additional 110,097 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Insider Activity

In other news, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $32.98, for a total value of $109,922.34. Following the completion of the transaction, the insider owned 84,974 shares in the company, valued at approximately $2,802,442.52. The trade was a 3.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 23,331 shares of company stock valued at $710,862. 29.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

JANX has been the subject of several research analyst reports. Cantor Fitzgerald cut their target price on shares of Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating for the company in a research note on Tuesday, December 2nd. Bank of America dropped their price objective on shares of Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, December 2nd. Wedbush restated an “outperform” rating and set a $45.00 price objective (down previously from $76.00) on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Stifel Nicolaus decreased their target price on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, December 2nd. Finally, Guggenheim assumed coverage on Janux Therapeutics in a research note on Wednesday, September 3rd. They set a “buy” rating and a $72.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Janux Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $62.67.

Janux Therapeutics Stock Down 1.2%

Janux Therapeutics stock opened at $15.12 on Tuesday. The company’s 50-day moving average price is $25.83 and its 200-day moving average price is $24.82. Janux Therapeutics, Inc. has a twelve month low of $14.85 and a twelve month high of $63.00. The company has a market cap of $909.47 million, a PE ratio of -9.00 and a beta of 2.82.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.21. The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.07 million. As a group, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.